Kyowa Kirin Co., Ltd.
JPX: 4151.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Abdul Hafeez Mullick
- Employees
- 5,669
- Headquarters
- Tokyo, Japan
- IPO year
- 2000
- Market cap
- ¥1.2T
- Website
- https://www.kyowakirin.com
Loading 4151…
Loading profile data…Frequently asked questions about 4151
What does Kyowa Kirin Co., Ltd. (4151.T) do?
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an an...
Where does 4151.T trade?
Kyowa Kirin Co., Ltd. (4151.T) trades on the Tokyo Stock Exchange.
What sector is 4151.T in?
Kyowa Kirin Co., Ltd. (4151.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Kyowa Kirin Co., Ltd.?
Abdul Hafeez Mullick is the chief executive officer of Kyowa Kirin Co., Ltd. (4151.T).
Where is Kyowa Kirin Co., Ltd. headquartered?
Kyowa Kirin Co., Ltd. is headquartered in Japan.
Does 4151.T pay a dividend?
Yes — Kyowa Kirin Co., Ltd. (4151.T) paid a trailing twelve-month dividend of JPY 62.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4151.T go public?
Kyowa Kirin Co., Ltd. (4151.T) completed its initial public offering in 2000.